Basilea's recent pivot has financially and strategically altered the company's dynamics. Our research note analysis the prospects for the company's anti-infectives business. The consequences of the strategic change have yet to be fully appreciated by investors, we believe.
The anti-infectives franchise has been dominated by Cresemba, Basilea's very successful antifungal. Cresemba's marketing partners are Astellas in the US and Pfizer in Europe. These highly credible partners demonstrate the imp ....
09 Nov 2022
Basilea - Sustainable profitability
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea - Sustainable profitability
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
09 Nov 2022 -
Author:
Brian White | Andrew Keith -
Pages:
21
Basilea's recent pivot has financially and strategically altered the company's dynamics. Our research note analysis the prospects for the company's anti-infectives business. The consequences of the strategic change have yet to be fully appreciated by investors, we believe.
The anti-infectives franchise has been dominated by Cresemba, Basilea's very successful antifungal. Cresemba's marketing partners are Astellas in the US and Pfizer in Europe. These highly credible partners demonstrate the imp ....